Retatrutide FDA Approval Status in 2026: Not Approved Yet
This page is informational and is not medical advice. Retatrutide is investigational and not for sale. NextGenGLP1 may earn a commission on partner links, at no cost to you. Partners on this page do not sell retatrutide.
· Last updated
As of 24 August 2026, retatrutide is not FDA-approved. Eli Lilly’s 23 July 2026 release said the company is completing the Chemistry, Manufacturing, and Controls (CMC) package required for a Biologics License Application (BLA) and plans to submit that BLA in Q1 2027. That 2026 status is investigational: a Q1 2027 filing is planned, and an FDA decision date is unknown.
What you can do now
- Join this site’s email list if you want a note when Lilly files or if FDA acts. The NextGenGLP1 waitlist is not a Lilly program and is not a consumer queue at Lilly.
- Talk with a clinician about FDA-approved options such as semaglutide or tirzepatide if weight-management care is appropriate for you. Lilly’s oral GLP-1 Foundayo (orforglipron) received FDA approval on 1 April 2026; that is an educational status note, not a partner offer on this page.
- Do not buy retatrutide, “research peptides,” or compounded retatrutide. The FDA told state boards of pharmacy on 31 March 2025 that compounded retatrutide does not meet the conditions for 503A or 503B exemptions (not a USP/NF monograph, not a component of an FDA-approved drug, not on the 503A or 503B bulks lists). On 12 August 2026, Lilly filed lawsuits and asked platforms to shut down illegal retatrutide sales. See Can you buy retatrutide?
What retatrutide is
Retatrutide is an investigational once-weekly injectable that activates three receptors: GIP, GLP-1, and glucagon. It has no brand name. It is not the same drug as tirzepatide (Mounjaro/Zepbound). A dedicated Phase 3 comparison, TRIUMPH-5 (NCT06662383), has not reported, so this page does not rank retatrutide against Zepbound from cross-trial percentages.
Q1 2027 BLA: what Lilly has actually said
On 23 July 2026, Lilly wrote that it “is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.” In a statement to CNBC the same day, Lilly said it needs more time to gather and verify manufacturing and quality-control data before it can seek approval.
Lilly reconfirmed the Q1 2027 BLA plan on its 5 August 2026 second-quarter earnings materials, noting that the clinical data package is complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain.
Whether FDA ultimately reviews a BLA versus an NDA is a live classification dispute, not a new filing date. BioSpace (5 August 2026) reported that FDA has treated retatrutide as not qualifying as a biologic, while Lilly intends to pursue a BLA. That dispute is a regulatory risk. It does not replace Lilly’s stated Q1 2027 filing plan with an invented approval year.
Filing is not approval. No PDUFA date exists until FDA accepts an application. This page does not assign a 2027 or 2028 approval year.
Phase 3 results (Lilly efficacy estimand unless noted)
Lilly reports a primary efficacy estimand (effect if participants stayed on study drug without starting prohibited weight-management treatments) and a treatment-regimen estimand (effect regardless of discontinuation). Efficacy-estimand percentages are higher. Where Lilly published the treatment-regimen figure, it is labeled below. These are not head-to-head results versus Zepbound.
TRIUMPH-4 — 11 December 2025
Adults with obesity or overweight and knee osteoarthritis, without diabetes. n=445. At 68 weeks, Lilly’s efficacy estimand: 12 mg −28.7% (about −71.2 lbs); 9 mg −26.4%; placebo −2.1%. Treatment-regimen 12 mg −23.7%. Dysesthesia: 20.9% on 12 mg vs 0.7% placebo. Source: Lilly, 11 Dec 2025.
TRIUMPH-1 — 21 May 2026 (ADA presentation 6 June 2026)
Pivotal obesity trial without type 2 diabetes. n=2,339. Efficacy estimand at 80 weeks: 12 mg −28.3%. In a pre-specified extension for baseline BMI ≥35, 12 mg reached −30.3% at 104 weeks. Treatment-regimen 12 mg −25.0% at 80 weeks. Source: Lilly, 21 May 2026.
TRANSCEND-T2D-1 — 6 June 2026, The Lancet
Type 2 diabetes inadequately controlled with diet and exercise. n=537. Baseline A1C about 7.9%. Headline results reported A1C reductions of up to 2.0% and 12 mg −16.8% body weight at 40 weeks. Source: Bajaj et al., The Lancet (6 June 2026); ADA 2026 simultaneous presentation.
TRIUMPH-2 — 23 July 2026
Obesity or overweight plus type 2 diabetes. n=1,152. Efficacy estimand at 80 weeks: 12 mg −20.8%. A1C reductions of up to 1.6% from a baseline of 7.7%. Source: Lilly, 23 Jul 2026.
TRIUMPH-3 — 23 July 2026
Severe obesity and established cardiovascular disease. n=1,949. Efficacy estimand: 12 mg −22.6% at 80 weeks. Pre-specified MACE analyses had confidence intervals that include 1.0 (MACE-5 HR 0.82, 95% CI 0.55–1.22; MACE-3 HR 1.12, 95% CI 0.64–1.96). This trial is not a dedicated CVOT. Source: Lilly, 23 Jul 2026.
The leftover “24%”: Phase 2, NEJM 2023
The widely quoted −24.2% at 48 weeks is from the Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023), not from Phase 3. This page does not lead with that figure as if it were TRIUMPH.
Timeline (as of 26 August 2026)
| Item | Status |
|---|---|
| Clinical package | Complete for planned obesity, OSA, and knee osteoarthritis submissions (Lilly, 23 Jul 2026; reconfirmed 5 Aug 2026) |
| CMC | In progress; additional manufacturing/quality-control work cited as the reason the filing is Q1 2027 rather than 2026 (Lilly via CNBC, 23 Jul 2026) |
| Planned U.S. filing | BLA in Q1 2027 (Lilly, 23 Jul 2026) |
| PDUFA date | None. No application has been accepted. |
| Approval year | Not announced. Filing is not approval. |
| Lilly consumer waitlist | None announced. This site’s email list is not a Lilly program. |
Sources
- Lilly TRIUMPH-4 topline, 11 Dec 2025
- Lilly TRIUMPH-1 topline, 21 May 2026
- Bajaj et al., TRANSCEND-T2D-1, The Lancet, 6 June 2026
- Lilly TRIUMPH-2 / TRIUMPH-3 and Q1 2027 BLA, 23 Jul 2026
- CNBC, 23 Jul 2026 (manufacturing/CMC delay)
- Lilly Q2 2026 earnings, 5 Aug 2026 (BLA plan reconfirmed)
- BioSpace, 5 Aug 2026 (BLA vs NDA dispute)
- FDA letter on compounded retatrutide / 503A–503B, 31 Mar 2025
- Lilly, 12 Aug 2026 (illegal retatrutide market)
- Jastreboff et al., Phase 2, N Engl J Med 2023 (−24.2% at 48 weeks)
- TRIUMPH-5, NCT06662383